Finding better ways to develop new drugs using protein kinases.
Improving Drug Development Through Studies of Protein Kinase Inhibitors
This study is looking for better ways to develop new medicines by focusing on proteins called kinases, using special compounds to help find promising drug targets faster, so that new treatments can reach patients more quickly.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11137791 on NIH RePORTER |
What this research studies
This research focuses on improving the drug development process, which is often lengthy and uncertain. By studying protein kinases, the research aims to identify new methods that can streamline the development of therapies. The team will utilize innovative compounds called ATP-allosteric bivalent inhibitors (AABIs) to target specific states of kinases, which could lead to faster identification of promising drug targets. The goal is to enhance the efficiency of drug discovery and ultimately bring new treatments to patients more quickly.
Who could benefit from this research
Good fit: Patients with conditions that are currently difficult to treat or for which new therapies are urgently needed would be ideal candidates to benefit from this research.
Not a fit: Patients with well-established treatment options or those not affected by conditions targeted by this research may not receive benefit.
Why it matters
Potential benefit: If successful, this research could lead to faster and more reliable development of new medications for various diseases.
How similar studies have performed: Other research has shown promise in improving drug development processes using similar innovative approaches, suggesting potential for success in this area.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Heppner, David E. — State University of New York at Buffalo
- Study coordinator: Heppner, David E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.